Physician profile
Andy T Lin
NPI 1104317791
$3,592.03
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $904 · 2021: $1,229 · 2022: $923.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $509.89 | 2019-2022 | |
| Csl Behring | $376.20 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $348.82 | 2019-2022 | |
| Amgen INC. | $302.60 | 2021-2022 | |
| Genentech USA, INC. | $278.30 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $241.37 | 2019-2022 | |
| Eisai INC. | $234.93 | 2020-2022 | |
| Biogen, INC. | $185.40 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $185.29 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $139.29 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $82.75 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $72.12 | 2019 | |
| Abbvie INC. | $71.19 | 2022 | |
| Saol Therapeutics INC. | $60.69 | 2020 | |
| Pfizer INC. | $53.25 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $43.32 | 2020 | |
| Boston Scientific Corporation | $43.10 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $41.63 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $36.64 | 2019 | |
| Chiesi USA, INC. | $36.20 | 2020-2021 | |
| Allergan, INC. | $33.56 | 2020-2021 | |
| Argenx US, INC. | $32.83 | 2022 | |
| Merz North America, INC. | $30.58 | 2019-2020 | |
| Grt US Holding, INC. | $28.74 | 2022 | |
| Tanabe Pharma America, INC. | $27.46 | 2021-2022 | |
| Acorda Therapeutics, INC | $25.11 | 2020 | |
| Shire North American Group INC | $20.95 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.31 | 2022 | |
| Ucb, INC. | $16.30 | 2022 | |
| Portola Pharmaceuticals, LLC | $16.21 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andy Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.